Quest Diagnostics Inc (NYSE:DGX) – Stock analysts at William Blair upped their Q1 2018 EPS estimates for shares of Quest Diagnostics in a research note issued on Tuesday. William Blair analyst A. Murphy now expects that the medical research company will earn $1.41 per share for the quarter, up from their previous forecast of $1.25. William Blair also issued estimates for Quest Diagnostics’ Q2 2018 earnings at $1.80 EPS, Q3 2018 earnings at $1.73 EPS, Q4 2018 earnings at $1.68 EPS, FY2018 earnings at $6.61 EPS, Q1 2019 earnings at $1.55 EPS and FY2019 earnings at $6.82 EPS.
Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Thursday, February 1st. The medical research company reported $1.40 EPS for the quarter, beating the Zacks’ consensus estimate of $1.37 by $0.03. Quest Diagnostics had a net margin of 10.00% and a return on equity of 15.41%. The firm had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.93 billion. During the same period in the previous year, the firm posted $1.31 earnings per share. The firm’s revenue was up 4.0% on a year-over-year basis.
Quest Diagnostics (NYSE:DGX) opened at $96.42 on Thursday. Quest Diagnostics has a 1 year low of $90.10 and a 1 year high of $112.96. The company has a market cap of $13,708.99, a P/E ratio of 17.53, a P/E/G ratio of 1.81 and a beta of 0.67. The company has a current ratio of 1.24, a quick ratio of 1.15 and a debt-to-equity ratio of 0.76.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 18th. Stockholders of record on Wednesday, April 4th will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.07%. This is a boost from Quest Diagnostics’s previous quarterly dividend of $0.45. The ex-dividend date is Tuesday, April 3rd. Quest Diagnostics’s payout ratio is presently 32.73%.
In other news, SVP Catherine T. Doherty sold 21,294 shares of the business’s stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $104.00, for a total value of $2,214,576.00. Following the completion of the sale, the senior vice president now directly owns 90,709 shares in the company, valued at $9,433,736. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Chairman Stephen H. Rusckowski sold 106,840 shares of the business’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $107.00, for a total transaction of $11,431,880.00. Following the completion of the sale, the chairman now owns 272,956 shares of the company’s stock, valued at $29,206,292. The disclosure for this sale can be found here. Insiders sold 192,014 shares of company stock valued at $19,950,134 over the last 90 days. 1.75% of the stock is owned by corporate insiders.
Several institutional investors have recently modified their holdings of the company. APG Asset Management N.V. lifted its stake in shares of Quest Diagnostics by 156.0% in the third quarter. APG Asset Management N.V. now owns 2,683,901 shares of the medical research company’s stock worth $251,320,000 after buying an additional 1,635,700 shares during the last quarter. Victory Capital Management Inc. raised its stake in Quest Diagnostics by 29.1% during the 4th quarter. Victory Capital Management Inc. now owns 2,487,295 shares of the medical research company’s stock valued at $244,974,000 after purchasing an additional 560,538 shares during the last quarter. Bessemer Group Inc. raised its stake in Quest Diagnostics by 73.1% during the 4th quarter. Bessemer Group Inc. now owns 2,107,796 shares of the medical research company’s stock valued at $207,596,000 after purchasing an additional 889,802 shares during the last quarter. American Century Companies Inc. raised its stake in Quest Diagnostics by 16.8% during the 4th quarter. American Century Companies Inc. now owns 2,039,110 shares of the medical research company’s stock valued at $200,832,000 after purchasing an additional 293,611 shares during the last quarter. Finally, Allianz Asset Management GmbH raised its stake in Quest Diagnostics by 10.5% during the 3rd quarter. Allianz Asset Management GmbH now owns 2,033,496 shares of the medical research company’s stock valued at $190,417,000 after purchasing an additional 193,829 shares during the last quarter. Institutional investors and hedge funds own 89.17% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://sportsperspectives.com/2018/02/09/q1-2018-eps-estimates-for-quest-diagnostics-inc-dgx-boosted-by-william-blair.html.
About Quest Diagnostics
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.